David Takes Up His Challenge Again

David had to postpone his plan to cycle 1000km in in thirty days through Singapore because of a health problem. Now he is fully recovered and feeling fit and well he intends to start again on July 1st. He is back into training hard and covered 36.46 km this morning despite the heat and humidity.…

Five Years On

This week marks the fifth anniversary of the launch of Secondary1st. In all that time we have been consistently amazed by the wonderful support we have received. This has enabled us to make five significant grants to research projects investigating different approaches to finding more effective treatments for secondary breast cancer; they can be found…

Challenges for Heather

Each member of the team from JH Mechanical Services has been challenged to walk or run 500 miles in the seven months between the beginning of April and the end of October to raise money for Secondary1st. Heather completed her 500 miles in less than eleven weeks. Then last weekend she and her friend Fiona…

Another Challenge For David

He planned to cycle 1000km in thirty days in the heat and humidity of Singapore to raise money for Secondary1st. In the first two days he covered more than 80 km so he was well on track to complete his challenge. Then a sudden flare-up of a health issue meant that David had to have…

Good Results From Parp Inhibitor Trial

A drug trial for Olaparib, also known as Lynparza, has shown good results for women with breast cancer who have faulty variants in BRCA1 or BRCA2 genes. In the trial 85.9% of women given Olaparib for one year after the end of treatment showed no return of the cancer for three years, compared with77.1% of…

A New Challenge for David

In 2017 David cycled all the way from London to Amsterdam to raise money for Secondary1st. He had recently lost his wife Joanne to secondary breast cancer and Secondary1st was a charity which had been very close to her heart. To continue his support David joined our team of Trustees to use his experience and…

The 10.500 mile Challenge

JH Mechanical Services are most generously continuing to raise funds for Secondary1st as their chosen charity. From the beginning of April to the end of October each member of their team will take on the “Walk 500 Challenge” and walk or run 500 miles to raise money for research into secondary breast cancer. Added together…

Tim did it

The sun was shining in a clear blue sky when Tim jumped… out of a plane 3 miles up. It had taken about 12 minutes for the Cessna Super Cargomaster to climb to the correct altitude. Then Tim and his tandem skydive instructor Alex were out in freefall, reaching a speed of 125 mph for…

More Challenges for Tracey

Tracey started 2020 with plans to take part in a number of events to raise more money for Secondary1st. She completed the 50km Winter Walk in London and was training for the 50km Easter Walk around Windsor, but it was cancelled because of the pandemic so she completed a virtual 50km challenge and booked in…

Up in the Air

Tim is planning to do something he’s never done before to raise funds for Secondary1st and increase awareness of secondary breast cancer; he’s going to skydive 10,000 feet from a plane. It will take about 15 minutes for the plane to reach its planned altitude. When he leaves the plane Tim will be in freefall…

A More Efficient Treatment Method

The NHS in England is introducing a more efficient way of administering a treatment for HER2 positive early and metastatic breast cancer. The new treatment is called Phesgo and is a combination of Perjeta (pertuzumab) and Herceptin (trastuzumab), two monoclonal antibodies. Phesgo uses new ENHANZE technology to deliver a sub-cutaneous fixed dose injection which can…

A Nice recommendation

Nice, the National Institute for Health and Care Excellence, has recommended the use of ribociclib, also known as Kisqali for routine use by the NHS in England and Wales, after it was originally made available through the Cancer Drugs Fund. Their draft guidance recommends ribociclib plus fulvestrant as an option for treating hormone receptor-positive, human…